Hyperuricemia impaired nitric oxide bioavailablity and deteriorated pulmonary arterial hypertension via a uric acid transporter, URATv1 in xanthine oxidoreductase (XOR)-independent manner

Back

ESC Premium Access

Hyperuricemia impaired nitric oxide bioavailablity and deteriorated pulmonary arterial hypertension via a uric acid transporter, URATv1 in xanthine oxidoreductase (XOR)-independent manner

Session: Pulmonary Hypertension: Targets for Therapies

Topic: Hypertension, Pulmonary Hypertension

Speaker: Doctor T. Watanabe (Fukuoka, JP)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Takanori Watanabe

Kyushu University Hospital, Fukuoka (Japan)

0 follower

6 more presentations in this session

A novel three-dimensional visualization system revealed an essential adaptive angiogenic response during the early phase of pulmonary hypertension

Speaker: Doctor T. Fujiwara (Tokyo, JP)

Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction

Speaker: Professor V. Schini-Kerth (Strasbourg, FR)

Pulmonary hypertension: reduction of vascular and cardiac remodeling by a new inhibitor of p38-alpha MAPK

Speaker: Miss G. Silva (Rio de Janeiro, BR)

Selective inhibition of Histone deacetylases reverses vascular remodelling and improves right ventricle function in pulmonary hypertension

Speaker: Doctor K. Kurakula (Amsterdam, NL)

Beta3-adrenergic stimulation restores endothelial mitochondrial dynamics and prevents pulmonary arterial hypertension

Speaker: Doctor E. Oliver (Madrid, ES)

Access the full session

Pulmonary Hypertension: Targets for Therapies

Speakers: Doctor T. Watanabe, Doctor T. Fujiwara, Professor V. Schini-Kerth, Miss G. Silva, Doctor K. Kurakula...

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources